Trial Profile
A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis
Status:
Suspended
Phase of Trial:
Phase I
Latest Information Update: 26 Jul 2023
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary) ; Caffeine; Dextromethorphan; Midazolam; Omeprazole; Vitamin K; Warfarin
- Indications Crohn's disease; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 21 Jul 2022 Planned primary completion date changed from 17 May 2022 to 1 Oct 2024.
- 01 Mar 2022 Status changed from recruiting to suspended.
- 03 Aug 2021 Planned End Date changed from 1 Aug 2024 to 1 Oct 2024.